Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025
Preprocedural M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial low-voltage area severity in atrial fibrillation undergoing catheter ablation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Shixin, Yang Xinqi, Peng Xiafeng, Yan Qing, Chen Zhenye, Gu Kai, Liu Hailei, Wang Zidun, Jiang Xiaohong, Li Mingfang, Chen Minglong, Chen Hongwu, Shi Jiaojiao
Аннотация
BACKGROUND: Autoantibodies against the M2-muscarinic acetylcholine receptor (anti-M2-R) have been implicated in atrial remodeling and atrial fibrillation (AF) pathogenesis. However, their relationship with atrial fibrosis severity, as assessed by low-voltage areas (LVAs), remains unclear.
METHODS: This prospective study included 164 patients (89 with paroxysmal AF [PAF], 75 with non-paroxysmal AF [NPAF]) undergoing first-time catheter ablation. Preprocedural plasma anti-M2-R levels were measured using ELISA. Left atrial LVAs were assessed via electroanatomic voltage mapping and categorized into four stages. Patients were grouped as having mild (≤ 20%) or moderate-to-extensive (>20%) LVA burden. Logistic regression and ROC curve analysis were used to evaluate predictors of LVA extent.
RESULTS: The anti-M2-R levels were significantly higher in NPAF patients than in PAF patients (282.8 ± 83.8 vs. 250.7 ± 74.2 ng/mL; p = 0.011). Patients with a moderate-to-extensive LVA size had higher anti-M2-R levels than those with mild LVA size (327.7 ± 85.1 vs. 251.4 ± 74.3 ng/mL; p < 0.001). In multivariate analysis, the anti-M2-R levels were significant predictor of moderate-to-extensive LVA size(OR per 10 ng/mL increase: 1.12; 95% CI: 1.05-1.20; p < 0.001). ROC analysis identified a cutoff value of 309.3 ng/mL for predicting extensive LVA (AUC: 0.75; sensitivity: 63%; specificity: 81%).
CONCLUSIONS: The preprocedural plasma anti-M2-R levels are independently associated with left atrial LVA severity in patients with AF and may serve as a minimally invasive biomarker for identifying patients with advanced atrial substrate, thereby guiding individualized ablation strategies.
METHODS: This prospective study included 164 patients (89 with paroxysmal AF [PAF], 75 with non-paroxysmal AF [NPAF]) undergoing first-time catheter ablation. Preprocedural plasma anti-M2-R levels were measured using ELISA. Left atrial LVAs were assessed via electroanatomic voltage mapping and categorized into four stages. Patients were grouped as having mild (≤ 20%) or moderate-to-extensive (>20%) LVA burden. Logistic regression and ROC curve analysis were used to evaluate predictors of LVA extent.
RESULTS: The anti-M2-R levels were significantly higher in NPAF patients than in PAF patients (282.8 ± 83.8 vs. 250.7 ± 74.2 ng/mL; p = 0.011). Patients with a moderate-to-extensive LVA size had higher anti-M2-R levels than those with mild LVA size (327.7 ± 85.1 vs. 251.4 ± 74.3 ng/mL; p < 0.001). In multivariate analysis, the anti-M2-R levels were significant predictor of moderate-to-extensive LVA size(OR per 10 ng/mL increase: 1.12; 95% CI: 1.05-1.20; p < 0.001). ROC analysis identified a cutoff value of 309.3 ng/mL for predicting extensive LVA (AUC: 0.75; sensitivity: 63%; specificity: 81%).
CONCLUSIONS: The preprocedural plasma anti-M2-R levels are independently associated with left atrial LVA severity in patients with AF and may serve as a minimally invasive biomarker for identifying patients with advanced atrial substrate, thereby guiding individualized ablation strategies.